Mrs. Terry Ridout, M. ED. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 60 Ne 25th St, Wilton Manors, FL 33305 Phone: 954-557-5203 |
Jennifer J. Rudnick, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1951 Ne 2nd Ave, I210, Wilton Manors, FL 33305 Phone: 954-249-1955 Fax: 954-566-5993 |
Kendall D Curtis Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1260 Ne 24th St Apt 1212, Wilton Manors, FL 33305 Phone: 470-783-4745 |
Derek Headley, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2704 Ne 8th Ave, Wilton Manors, FL 33334 Phone: 954-218-2184 |
Clare R Singer, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 917 Ne 29th Dr, Wilton Manors, FL 33334 Phone: 954-292-6894 |
News Archive
A team led by researchers at UC Santa Cruz has developed chip-based technology for reliable detection of Ebola virus and other viral pathogens. The system uses direct optical detection of viral molecules and can be integrated into a simple, portable instrument for use in field situations where rapid, accurate detection of Ebola infections is needed to control outbreaks.
Investigators in The Research Institute at Nationwide Children's Hospital have identified the role of a protein that could potentially lead to new clinical treatments to combat musculoskeletal diseases, including Duchenne muscular dystrophy (DMD).
Short-stay inpatient hospitalizations for children and adolescents with a psychiatric diagnosis increased significantly over a 12-year period (1996 to 2007) and decreased for the elderly, according to a report in the early online edition in Archives of General Psychiatry by Joseph C. Blader, Ph.D., Assistant Professor, Department of Psychiatry & Behavioral Science at Stony Brook University School of Medicine.
The Food and Drug Administration has cleared the MAGNETOM Vida 3 Tesla (3T) magnetic resonance imaging (MRI) scanner from Siemens Healthineers, which features new BioMatrix technology that addresses inherent anatomical and physiological differences among patients, as well as user variability.
Researchers have discovered a new class of drug that has the potential to help cancer patients who no longer respond to existing therapies.
› Verified 9 days ago